AlphAIalphai — Financial news for AI agents
BenzingaAUG 74 min read$LLY

Why Are Weight-Loss Stocks Gaining Thursday? - Viking Therapeutics (NASDAQ:VKTX), Novo Nordisk (NYSE:NVO), Structure Therapeutics (NASDAQ:GPCR), Terns Pharma (NASDAQ:TERN)

Eli Lilly's orforglipron showed 12.4% weight loss vs. 0.9% with placebo, below the 15% expected. Novo Nordisk's CagriSema showed up to 22.7% weight loss over 68 weeks in trials. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

Original reporting
Benzinga · Vandana Singh
Published Aug 7, 2025, 1:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2025, 2:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Are Weight-Loss Stocks Gaining Thursday? - Viking Therapeutics (NASDAQ:VKTX), Novo Nordisk (NYSE:NVO), Structure Therapeutics (NASDAQ:GPCR), Terns Pharma (NASDAQ:TERN) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$LLYNeutralMed
01

Why it matters

The underperformance of Eli Lilly's drug contrasted with Novo Nordisk's success may lead to a re-evaluation of competitive positioning within the weight-loss therapeutics market.

02

Market read

The news highlights competitive dynamics in the weight-loss drug market, influencing biotech and pharmaceutical stocks.

03

What to watch

Market reaction may be influenced by broader biotech sector trends and investor sentiment shifts unrelated to trial data.

Timing: short to medium term (next 1-3 months)

Background

Recent clinical trial data for weight-loss drugs from Eli Lilly and Novo Nordisk have garnered significant attention, impacting investor sentiment and stock prices.

Company-level read

Ticker impact

$LLYNeutralMedium confidence
Context

Eli Lilly's weight-loss drug data results.

Expected impact

Potential short-term negative impact on Eli Lilly (LLY), with possible positive momentum for competitors such as Novo Nordisk (NVO). Long-term effects depend on upcoming trial results and market acceptance.

Evidence & confidence

The data indicates Eli Lilly's recent trial did not meet expectations, which may temporarily dampen investor confidence. However, competitive advantages of other drugs suggest a potential shift favoring competitors.

$GPCRNeutralLow confidence
Context

Structure Therapeutics' involvement in weight-loss treatments.

Expected impact

Limited immediate impact; monitor for any future developments.

Evidence & confidence

Relevance score of 0.322374 indicates limited influence from this news on GPCR's stock.

$NVOBullishHigh confidence
Context

Novo Nordisk's promising weight-loss trial results.

Expected impact

Likely upward movement in NVO stock, especially if market perceives sustained efficacy.

Evidence & confidence

Robust trial data supports a favorable outlook; market sentiment aligns with potential growth.

Market effects

Sector

Potential shift in investor focus towards weight-loss therapeutics, impacting biotech and pharmaceutical sectors.

Regional

Primarily US and European markets where these companies are listed.

Global

Moderate; weight-loss drug market is globally significant, with ongoing competition.

Counterpoint

What could challenge this read

Eli Lilly's data may improve with further analysis or additional trial phases, potentially reversing short-term negative sentiment.

Key entities

  • Pharmaceutical Company
    Eli Lilly

    Developer of forforglipron, a weight-loss medication.

  • Pharmaceutical Company
    Novo Nordisk

    Known for CagriSema, demonstrating high efficacy in weight-loss trials.

Read at source← All news

Related articles

AUG 8
$LLYMedAI 8/10

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly (LLY) reported Q2 U.S. revenue up 33% led by ZEPBOUND and MOUNJARO volume, while U.S. price fell 3% (9% excluding rebate and discount estimate changes). International revenue rose in constant currency, with MOUNJARO a key driver. Lilly raised its 2026 revenue outlook to $85B-$87B and guided non-GAAP EPS $35.50-$36.50. It also discussed Medicare GLP-1 coverage expansion and retatrutide Phase III results.

yahoo.com7 min
AUG 7
$LLYMedAI 8/10

Eli Lilly and Company Q2 2026 Earnings Call Summary

Eli Lilly reported Q2 2026 drivers including 48% revenue growth, with Zepbound and Mounjaro adding $6.3B incremental growth versus prior year, and gross margin rising to 86.3%. Full-year revenue guidance was raised to $85B–$87B. Management discussed Foundayo U.S. scaling, Medicare GLP-1 Bridge access for 20M Americans, and planned retatrutide registrations in Q1 2027.

yahoo.com7 min
AUG 7
$LLYHighAI 9/10

Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Eli Lilly shares rose up to 7% after Q2 revenue jumped 48% to $22.97B, beating Wall Street by over $2B. Mounjaro and Zepbound totaled $14.87B, about 65% of revenue. Lilly lifted its 2026 outlook to $85B-$87B. Novo Nordisk also raised guidance, but U.S.-listed shares fell after Wegovy pill sales missed expectations.

yahoo.com6 min
AUG 7
$NVOMed

A promising heart drug fails, challenging a long-held theory of disease

Novo Nordisk’s Zeus trial of ziltivekimab in 6,300+ patients with heart disease or advanced kidney disease reduced inflammation biomarkers IL-6 and CRP, but did not lower cardiovascular events or deaths. Novo said it will continue two other ziltivekimab studies, ending in 2027. The results challenge the inflammation hypothesis for atherosclerosis.

nzherald.co.nz7 min